End ogenous glucoco rticoids regulate the metabolism of carbohydrates, proteins, lipids,and other substances throughout the body. Their effect is global, as almost every cellul ar structure has steroid receptors. They also have an effect on fluid and electrolyte balance, the body's environmental and natural stress, and the function of the kidneys, muscles, and the cardiovascular, immune, and endocrine systems.
Ototopical dexamethasone
Littl e infor mation exists on the sys temic effec ts of ototopi cal steroids . Two studies have provid ed us with basic kno wledge on this subject:
• Abra ham et al co nducted a single-blind, placeboco ntro lled experi ment in IO beagles.' Th e dogs were administere d two daily doses of a dexa methaso ne gel app lied to the outer auditory ca nal in one ear (60 ug/kg) for 2 I days. The authors noted several systemic effec ts. Polyd ipsia and polyuri a occ urred dur ing treatm ent , but it resolved 7 days after treatm ent was stopped. Statistic ally sig nifica nt plasma cort isol suppress ion was noted on days I I through 19 of thera py, but corti sol conce ntrations returne d to normal I wee k after the cessation of treatment. Addi tionally, cortiso l response to adrenocorticotrophic horm one (ACT H) stimulation was blocked during the ex per iment. Live r enzyme levels rose by day I I, but there was no change in electrolyte and leukocyte counts. No cli nical abnormalities of the externa l auditory ca nal, the ski n, or the cuta neou s pigment were obse rve d. One unfortun ate aspec t of this study is that the authors did not measure plasma dexameth asone concent rations.
• In a study designed to assess the pharm acokinetics of the ototop ical ciprofloxaci n/dex amethaso ne co mbinatio n, we measured plasm a dexam eth asone co nce ntratio ns in 25 children who were undergoin g tympanos tomy tube insertion.' Each child rece ive d a single dose (4 drops) of the ototopica l co mbination cipro floxac in/dexametha sone (840/280 ug) in a steriIe suspension. We then measure d the plasm a co nce ntrations of both dru gs at 15 and 30 minutes and at I , 2, 4, and 6 hour s by high-performance liqui d chromatogra phy/tandem mass spectrometry. Plasm a dexameth asone level s were detectable in 14 of these children. The peak conce ntration level (mea n: 0.90 ± 1.04 ng/ml ; range : <0.05 to 5.10) was reached fairly qui ckly-within 2 hou rs ( figure) . Th e half-li fe was 3.9 hours (±2.9) . Th ese findings indicate that the deg ree of sys temic ex pos ure to dexamethasone followi ng oto top ical adm inis tration in pediatric pat ien ts is low. We did not inves tiga te ACTH levels, but it is un likely that dexameth asone triggered any significant suppression of the HPA axis at the plasm a levels recorded in this study. c Comp ared with oral administration, ototopical administration of dex am eth asone res ults in significantly lower plasma concentrations. Whi le an ora l dose of500 ug of dexameth asone will result in a seru m concentration of 0.0 08 ug/ml , an ototopical dose of 280 ug will yield a plasma co ncentration of only 0.001 to 0.002 ug/ml , The systemic effect s of ototopical dex ameth asone are dependent on its absorption via the middl e ear structures. Absorption is dependent on the clinical state of the tymp anum-that is, absorption is decrea sed whe n Figure. Graph shows plasma dexamethasone concentration after a single dose of ciprothe mucosa is edem atous and floxacin/dexa methasone. fluid is pre sent. Absorpti on is also depend ent on the limited total dosage applied to the middle ea r; comp ared with parenteral administration, topical administration deli vers only minim al amounts of dexameth asone to the middle ear in each application.
Several animal and hum an studies have involved various methods of deliverin g dexamethasone transtyrnpanically.5.6 These studies dem onstrated round window perm eability, with measurable levels of drug in the perilymph. Plasma concentrations of dexamethasone are significantly lower after transtymp anic application than after oral or intra venous admini stration. Regrettably, these studies did not include any objecti ve measurements of systemic effect s or pharmacokinetic properties; however, no evidence of adverse systemic reactions was observed. Moreover, many studies have demon strated the effectiveness of ototopical dexamethasone for the treatm ent of sudden hearing loss, Meniere's disea se, tinnitu s, and otitis media , and none of these studies demonstrated any evidence of ototoxicity.
Conclusion
Ototopical administration of dexameth asone produ ces beneficial therapeutic effects in a numb er of otolog ic conditi ons. Plasma levels of ototopically administere d dexameth asone are detectable only when measured by sophisticated and highly sensitive techniques. Admini stration of transtymp anic dexamethasone in high concentrations and over a prolonged period of time temp orarily sup-
